Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Pridopidine in Early Stage Huntington Disease
2020-002822-10Phase 3Completed
- Sponsor
- Prilenia Therapeutics
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Huntington disease (HD) comparing Pridopidine with Placebo (2 arms). Primary endpoint: Change in UHDRS Total Functional Capacity. Started Nov 2020; status: completed.
02
Drugs
pridopidine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2020-002822-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002822-10.